Daewoong Pharmaceutical said that it has confirmed that Nabota, its botulinum toxin, is effective in improving sleep bruxism, also known as nocturnal tooth grinding, and published the results in an international journal.
|Daewoong Pharmaceutical has published the results of a study proving Nabota’s efficacy in treating sleep bruxism in an international journal. (Daewoong)|
In the clinical study, conducted by Professor Kim Seong-taek at Yonsei University College of Dentistry, the team confirmed the effect of reducing the power of the pedicle muscles that affect bruxism when administering Nabota to patients suffering from sleep bruxism. The pedicle muscle is one of the masticatory muscles on the side of the jaw.
In detail, after administering either Nabota or placebo to the muscles, the researchers measured the intensity of the force entering the muscles by measuring maximal voluntary clenching and rhythmic masticatory muscle activity through polysomnography.
As a result, the subjects who received Nabota had weaker muscle strength than the placebo group, which, in turn, relieved symptoms such as chewing. The team also confirmed that the drug's effect was maintained for 12 weeks while reporting no serious adverse events related to the drug.
"The study confirmed the effect of reducing bruxism symptoms when Nabota was administered to sleep bruxism patients," Professor Kim said.
Park Sung-soo, head of Daewoong's Nabota business division, also said, "As the study evidenced the effect of Nabota in reducing the strength of masticatory muscles associated with sleep bruxism, the company has managed to confirm additional potential therapeutic indications of Nabota as well as beauty."
The company will continue to prove Nabota's differentiated competitiveness through various research activities, he added.
The results of the research were published in the journal, Toxins.
<© Korea Biomedical Review, All rights reserved.>